Literature DB >> 15082847

Systemic cytomegalovirus infection complicating ulcerative colitis: a case report and review of the literature.

P J Hamlin1, M N Shah, N Scott, J I Wyatt, P D Howdle.   

Abstract

Cytomegalovirus is a common infection worldwide and in the immunocompromised individual it can be a major cause of morbidity and mortality. In patients with inflammatory bowel disease cytomegalovirus infection has been described in both immunocompetent and immunocompromised individuals. A 34 year old man with an exacerbation of his colitis was diagnosed as having both cytomegalovirus colitis and hepatitis. The diagnosis was made on the classical appearance of "owl's eye" inclusion bodies on colonic and hepatic biopsies and, in addition, viral serology and polymerase chain reaction (PCR) analysis of the cytomegalovirus DNA copy number. Fourteen days of treatment with ganciclovir led to a prompt improvement in the symptoms of colitis, resolution of the pyrexia, normalisation of the liver function tests, and clearance of the virus, as measured by a negative cytomegalovirus DNA PCR. Cytomegalovirus infection is a potentially fatal complication of treatment induced immunosuppression in patients with inflammatory bowel disease. As in this case, infection may be systemic and not confined to the intestine. Prompt diagnosis using histology, serology, and PCR analysis allows prompt introduction of therapy and an improved prognosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15082847      PMCID: PMC1742981          DOI: 10.1136/pgmj.2003.007385

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  10 in total

1.  Cytomegalovirus, inflammatory bowel disease, and anti-TNFα.

Authors:  Sara T Campos; Francisco A Portela; Luís Tomé
Journal:  Int J Colorectal Dis       Date:  2017-01-13       Impact factor: 2.571

2.  Cytomegalovirus colitis in children with inflammatory bowel disease.

Authors:  B Ghidini; M Bellaiche; D Berrebi; J Viala; J P Hugot; J F Mougenot; A Munck; M Peuchmaur; J P Cezard
Journal:  Gut       Date:  2006-04       Impact factor: 23.059

3.  Cytomegalovirus Reactivation in Ulcerative Colitis Patients.

Authors:  Minh Nguyen; Kara Bradford; Xiaolan Zhang; David Q Shih
Journal:  Ulcers       Date:  2011-01-01

Review 4.  Cytomegalovirus and ulcerative colitis: Place of antiviral therapy.

Authors:  Sylvie Pillet; Bruno Pozzetto; Xavier Roblin
Journal:  World J Gastroenterol       Date:  2016-02-14       Impact factor: 5.742

5.  Diagnosing cytomegalovirus in patients with inflammatory bowel disease--by immunohistochemistry or polymerase chain reaction?

Authors:  Nina Zidar; Ivan Ferkolj; Katja Tepeš; Borut Štabuc; Nika Kojc; Tina Uršič; Miroslav Petrovec
Journal:  Virchows Arch       Date:  2015-02-21       Impact factor: 4.064

6.  Acute cytomegalovirus infection is a risk factor in refractory and complicated inflammatory bowel disease.

Authors:  Maha M Maher; Mahmoud I Nassar
Journal:  Dig Dis Sci       Date:  2008-12-18       Impact factor: 3.199

7.  Colitis due to Cytomegalovirus and Herpes Simplex Type 2 as a Complication of a First Presentation of Inflammatory Bowel Disease.

Authors:  Tiago Leal; Bruno Arroja; Dalila Costa; Carla Ferreira; João Bruno Soares; Raquel Gonçalves
Journal:  GE Port J Gastroenterol       Date:  2021-03-23

8.  Primary infection with cytomegalovirus in ulcerative colitis.

Authors:  Stanley I Martin; Alireza Sepehr; Jay A Fishman
Journal:  Dig Dis Sci       Date:  2006-11-22       Impact factor: 3.487

9.  Cytomegalovirus-Related Hospitalization Is Associated With Adverse Outcomes and Increased Health-Care Resource Utilization in Inflammatory Bowel Disease.

Authors:  Cheng Zhang; Somashekar G Krishna; Alice Hinton; Razvan Arsenescu; Edward J Levine; Darwin L Conwell
Journal:  Clin Transl Gastroenterol       Date:  2016-03-10       Impact factor: 4.488

Review 10.  Detection of cytotoxic CD13-specific autoantibodies in sera from patients with ulcerative colitis and Crohn's disease.

Authors:  A Rahbar; L Boström; C Söderberg-Naucler
Journal:  J Autoimmun       Date:  2006-04-11       Impact factor: 7.094

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.